News

FDA Approves Pertuzumab for Metastatic HER2+ Breast Cancer

Publish date: June 11, 2012

 

* This story was updated on 11/30/2012.

Pages

Recommended Reading

Trastuzumab Raises Cardiotoxicity Fivefold in Breast Cancer Patients
MDedge ObGyn
Oncologists Favor Psychosocial Care, But Give It Short Shrift
MDedge ObGyn
FDA Panel Endorses Ultrasound System for Screening Dense Breasts
MDedge ObGyn
Breast Brachytherapy Doubles Mastectomy Risk
MDedge ObGyn
Surgery for DCIS Saves Lives
MDedge ObGyn
Breast Brachytherapy Judged Superior in Tumor Bed Control
MDedge ObGyn
Docs Need Primer on Long-Term Effects of Chemotherapy
MDedge ObGyn
T-DM1 Tops Capecitabine-Lapatinib in Advanced HER2-Positive Breast Cancer
MDedge ObGyn
Hodgkin's Survivors Face High Breast Cancer Risk
MDedge ObGyn
Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy
MDedge ObGyn

Related Articles